GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Pharmaceutical companies may deal in generic medications and medical devices without the involvement of intellectual property ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...

Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

[208] AS04 is another EU-registered adjuvant present in an HPV vaccine (Cervarix) as well as in a Hepatitis B vaccine (Fendrix® [GSK Biologicals]). For this adjuvant, no effect on any of the ...

Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...

Listing Sanofi and GlaxoSmithKline as firms that left the country due ... "The order targets healthcare products including pharmaceuticals, diagnostics, medical devices, biologicals and medical ...

GlaxoSmithKline is to team up with two UK ... in target validation Target validation involves defining the underlying biological processes which cause disease, but around 90% of compounds fail ...